title: Endoscopic patterns and histopathological features after eradication therapy in Helicobacter pylori-associated nodular gastritis.
abstract: The endoscopic finding of nodular gastritis (NG) is highly associated with presence of Helicobacter pylori infection. How the endoscopic patterns and histopathology of NG change after eradication of H. pylori is unclear. Twenty-one adults (3 men and 18 women) with H. pylori-associated NG found on endoscopy were enrolled for this study. The histological findings included gastritis activity, bacterial colonization, and lymphoid follicles. Repeat endoscopy for the endoscopic as well as histopathological features of gastric biopsy specimens was performed 2 months later after eradication treatment. H. pylori was successfully eradicated in 19 patients. Endoscopic NG disappeared in 12, improved in 5, and was unchanged in 4. After treatment, there was significant improvement in scores for gastritis activity [P < 0.001, 95% confidence interval (CI) 1.31-1.91], bacterial colonization (P < 0.001, 95% CI 0.71-1.14) and follicular gastritis (P = 0.047, 95% CI 0.04-0.52), primarily among patients whose endoscopic pattern resolved completely. The disappearance of nodularity on endoscopy was accompanied by a decrease in follicular gastritis score.
authors: Department of Gastroenterology, Mackay Memorial Hospital and Mackay Medicine, Nursing and Management College, No. 92, Sec. 2, Chung-Shan N. Road, Taipei 104, Taiwan, Republic of China. mingjen.ch@msa.hinet.net
authors: Ming-Jen
authors: MJ
authors: Chen
authors: Shou-Chuan
authors: SC
authors: Shih
authors: Tsang-En
authors: TE
authors: Wang
authors: Yu-Jan
authors: YJ
authors: Chan
authors: Chih-Jen
authors: CJ
authors: Chen
authors: Wen-Hsiung
authors: WH
authors: Chang
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage; D000328:Adult; D000477:Alkylating Agents / Q000008:administration & dosage; D000658:Amoxicillin / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D001706:Biopsy; D004359:Drug Therapy, Combination; D005260:Female; D005756:Gastritis / Q000188:drug therapy* / Q000382:microbiology* / Q000473:pathology; D005773:Gastroscopy; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000473:pathology; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014011:Tinidazole / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000477:Alkylating Agents; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D014011:Tinidazole; D064747:Lansoprazole; D000658:Amoxicillin